Salvia BioElectronics

Salvia BioElectronics

Private
Eindhoven, North BrabantHealthcare & Life Scienceshttps://www.salviabioelectronics.com

Last Round

Series B

May 27, 2025

Total Funding Raised

$91M

Momentum Score

25 /100

Company Overview

Salvia BioElectronics is a bioelectronics company that develops innovative technology to aid in the treatment of chronic neurological diseases through smart devices that utilize mild electrical impulses to modulate nerve activity, offering a neurostimulation alternative for patients with drug-refractory migraines.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Non-AI

Keywords

neuromodulation therapychronic migraine treatmentimplantable medical deviceneurostimulationbioelectronicselectroceuticalsmigraine devicedrug-free therapyminimally invasive implantbioelectronic medicineFDA Breakthrough Devicepain managementpatient-controlled deviceclinical-stage company

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Salvia BioElectronics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Salvia BioElectronics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMay 27, 2025
DebtSep 22, 2020
Series ASep 22, 2020

Key People

Founding team and executive leadership

Daniel Schobben

Chief Operating Officer Founder

Founding Team

Hubert Martens

CEO Founder

Founding Team

Jeroen Siemes

Chief Financial Officer

Executive Team

Salvia BioElectronics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Neuromodulation therapy for chronic migraine is currently being evaluated in clinical studies.

  • Oct 7, 2025

    Developing 'MySalvia Therapy', a neuromodulation treatment for chronic migraine.

Salvia BioElectronics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Salvia BioElectronics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Salvia BioElectronics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEindhoven, North Brabant
Employee Range63
Year Founded2017
Last FundingMay 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.